newsfilter
← Latest News
PR Newswire·

Halozyme to Report First Quarter 2026 Financial and Operating Results

  • Halozyme Therapeutics, Inc. will release its first quarter 2026 financial & operating results on Monday, May 11, 2026, following the close of trading.
  • A conference call to discuss the results is scheduled for May 11, 2026, at 1:30pm PT/4:30pm ET.
  • The conference call can be accessed live with pre-registration via a provided link, with a webcast & replay available on the company's investor website.
  • Halozyme's ENHANZE® drug delivery technology, utilizing rHuPH20, has been used in ten commercialized products across over 100 global markets, affecting more than one million patient lives.
  • ENHANZE® is licensed to major partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen, Merus N.V., & Skye Bioscience.
  • The company expanded its portfolio with Hypercon™, a microparticle technology for hyperconcentration licensed to partners such as Janssen, Eli Lilly, argenx, & Vertex Pharmaceuticals.
  • Halozyme also utilizes Surf Bio's polymer-based hyperconcentration technology to broaden subcutaneous delivery options for biologics.
  • Proprietary commercial products include Hylenex® & XYOSTED®, while the company maintains development programs with Teva Pharmaceuticals & McDermott Laboratories Limited (an affiliate of Viatris Inc.).
  • Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; & Boston, MA, where its operations facility is located.
  • Investor inquiries can be directed to Tram Bui, VP of Investor Relations & Corporate Communications, or Sydney Charlton of Teneo.